[go: up one dir, main page]

MX2019011649A - Forma solida de (s)-[2-cloro-4-fluoro-5-(7-morfolin-4-il-quinazoli n-4-il)fenil]-(6-metoxi-piridazin-3-il)-metanol. - Google Patents

Forma solida de (s)-[2-cloro-4-fluoro-5-(7-morfolin-4-il-quinazoli n-4-il)fenil]-(6-metoxi-piridazin-3-il)-metanol.

Info

Publication number
MX2019011649A
MX2019011649A MX2019011649A MX2019011649A MX2019011649A MX 2019011649 A MX2019011649 A MX 2019011649A MX 2019011649 A MX2019011649 A MX 2019011649A MX 2019011649 A MX2019011649 A MX 2019011649A MX 2019011649 A MX2019011649 A MX 2019011649A
Authority
MX
Mexico
Prior art keywords
pyridazin
fluoro
chloro
methoxy
phenyl
Prior art date
Application number
MX2019011649A
Other languages
English (en)
Other versions
MX394899B (es
Inventor
Fuchss Thomas
Kuehn Clemens
Poma Marco
Burini Edoardo
Lange Michael
Maillard David
BREUNING Marcel
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of MX2019011649A publication Critical patent/MX2019011649A/es
Publication of MX394899B publication Critical patent/MX394899B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D9/00—Crystallisation
    • B01D9/005—Selection of auxiliary, e.g. for control of crystallisation nuclei, of crystal growth, of adherence to walls; Arrangements for introduction thereof
    • B01D9/0054—Use of anti-solvent
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invención se refiere a (S)-[2-cloro-4-fluoro-5-(7-morf olin-4-ilquinazolin-4-il)fenil]-(6-metoxi-piridazin-3-il)-metanol cristalino desordenado anhidro, así como un método para producir el mismo, y composiciones farmacéuticas y usos médicos del mismo.
MX2019011649A 2017-03-30 2018-03-28 Forma solida de (s)-[2-cloro-4-fluoro-5-(7-morfolin-4-il-quinazolin-4-il)fenil]-(6-metoxi-piridazin-3-il)-metanol. MX394899B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17163826 2017-03-30
PCT/EP2018/057875 WO2018178133A1 (en) 2017-03-30 2018-03-28 Solid form of (s)-[2-chloro-4-fluoro-5-(7-morpholin-4-ylquinazolin-4-yl)phenyl]-(6-methoxy-pyridazin-3-yl)methanol

Publications (2)

Publication Number Publication Date
MX2019011649A true MX2019011649A (es) 2019-12-19
MX394899B MX394899B (es) 2025-03-24

Family

ID=58461171

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019011649A MX394899B (es) 2017-03-30 2018-03-28 Forma solida de (s)-[2-cloro-4-fluoro-5-(7-morfolin-4-il-quinazolin-4-il)fenil]-(6-metoxi-piridazin-3-il)-metanol.

Country Status (16)

Country Link
US (1) US11053233B2 (es)
EP (1) EP3601265B1 (es)
JP (1) JP7365904B2 (es)
KR (1) KR20190136037A (es)
CN (1) CN110446705B (es)
AU (1) AU2018246257B2 (es)
CA (1) CA3058285C (es)
DK (1) DK3601265T3 (es)
ES (1) ES2956036T3 (es)
IL (1) IL269667B2 (es)
MX (1) MX394899B (es)
RU (1) RU2019133577A (es)
SG (1) SG11201909059XA (es)
TW (1) TWI781161B (es)
WO (1) WO2018178133A1 (es)
ZA (1) ZA201907144B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102013008118A1 (de) * 2013-05-11 2014-11-13 Merck Patent Gmbh Arylchinazoline
ES2926628T3 (es) * 2017-03-30 2022-10-27 Merck Patent Gmbh Forma cristalina de (S)-[2-cloro-4-fluoro-5-(7-morfolin-4-ilquinazolin-4-il)fenil]-(6-metoxi-piridazin-3-il)-metanol
WO2020259613A1 (zh) 2019-06-27 2020-12-30 南京明德新药研发有限公司 作为dna-pk抑制剂的喹啉和噌啉衍生物
CN116670128A (zh) * 2020-12-28 2023-08-29 南京明德新药研发有限公司 吗啉取代的苯并嘧啶类化合物的晶型及其制备方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IN191496B (es) * 1999-07-30 2003-12-06 Ranbaxy Lab Ltd
GB2383042A (en) * 2001-10-18 2003-06-18 Cipla Ltd Amorphous alendronate sodium
US7655692B2 (en) * 2003-06-12 2010-02-02 Pfizer Inc. Process for forming amorphous atorvastatin
WO2008099887A1 (ja) * 2007-02-16 2008-08-21 Eisai R & D Management Co., Ltd. メチル ｎ－［３－（６，７－ジメトキシ－２－メチルアミノキナゾリン－４－イル）フェニル］テレフタラミックアシッドの結晶、非晶質体または塩
CA2712005C (en) * 2008-02-05 2014-04-15 Harbor Biosciences, Inc. Pharmaceutical solid state forms
IT1404157B1 (it) * 2010-12-30 2013-11-15 Nano Active Film S R L Forma cristallina nanoporosa disordinata di polistirene sindiotattico, suo processo di preparazione e articoli comprendenti la stessa.
DE102013008118A1 (de) 2013-05-11 2014-11-13 Merck Patent Gmbh Arylchinazoline
RU2019134551A (ru) * 2013-05-30 2019-11-22 Инфинити Фармасьютикалз, Инк. Лечение злокачественных опухолей с использованием модуляторов изоформ pi3-киназы
US10905146B2 (en) * 2013-07-12 2021-02-02 The Coca-Cola Company Compositions for improving rebaudioside M solubility
BR112017026406A2 (pt) * 2015-06-12 2019-04-02 Adhaere Pharmaceuticals, Inc. formas sólidas de ácido (z)-4-(5-((3-benzil-4-oxo-2-tioxotiazolidin-5-ilideno)metil)furan-2-il)benzoico

Also Published As

Publication number Publication date
AU2018246257A1 (en) 2019-11-14
CN110446705B (zh) 2023-04-14
IL269667B1 (en) 2024-05-01
TW201900634A (zh) 2019-01-01
KR20190136037A (ko) 2019-12-09
TWI781161B (zh) 2022-10-21
DK3601265T3 (da) 2023-09-18
CN110446705A (zh) 2019-11-12
SG11201909059XA (en) 2019-10-30
IL269667B2 (en) 2024-09-01
AU2018246257A8 (en) 2019-11-28
RU2019133577A (ru) 2021-04-30
IL269667A (en) 2019-11-28
CA3058285A1 (en) 2018-10-04
RU2019133577A3 (es) 2021-07-30
MX394899B (es) 2025-03-24
EP3601265B1 (en) 2023-06-21
ZA201907144B (en) 2023-10-25
WO2018178133A1 (en) 2018-10-04
AU2018246257B2 (en) 2022-05-12
US20200123144A1 (en) 2020-04-23
ES2956036T3 (es) 2023-12-12
JP2020512362A (ja) 2020-04-23
CA3058285C (en) 2024-02-06
JP7365904B2 (ja) 2023-10-20
US11053233B2 (en) 2021-07-06
EP3601265A1 (en) 2020-02-05

Similar Documents

Publication Publication Date Title
SA519401180B1 (ar) مركبات بيروليزين بها استبدال واستخداماتها
GT201700146A (es) Compuestos de triazolopirimidina y usos de los mismos
UY35675A (es) Derivados sustituidos de quinazolin-4-ona
MX2019007079A (es) Compuestos de aminotiazol como inhibidores de c- kit.
CL2018001230A1 (es) Tratamiento de osteoartritis
CO2017001884A2 (es) Polimorfos de selinexor
PH12017500416A1 (en) Compounds and compositions as raf kinase inhibitors
MX2017004200A (es) Compuestos de heteroarilo como inhibidores de tirosina-cinasa de bruton (btk) y usos de estos.
MX2021005052A (es) Oxiesteroles y métodos de uso de los mismos.
DOP2015000157A (es) Lactamas fusionadas de arilo y heteroarilo
UY35663A (es) Derivados de piperidinil-indol como inhibidores del factor de complemento b y usos de los mismos
EA201691302A1 (ru) Новые гетероциклические соединения
GT201300174A (es) Compuestos de indol o análogos de los mismos útiles para el tratamiento de la degeneración macular relacionada con la edad (dme)
CU20160192A7 (es) Derivados de indano e indolina útiles como activadores de la guanilato ciclasa soluble
MX389753B (es) Compuestos triciclicos y su uso como inhibidores de la fosfodiesterasa
MX2017016619A (es) Derivados de pirimidina como inhibidores de tirosina cinasa de bruton (btk) y usos de los mismos.
MX2019011649A (es) Forma solida de (s)-[2-cloro-4-fluoro-5-(7-morfolin-4-il-quinazoli n-4-il)fenil]-(6-metoxi-piridazin-3-il)-metanol.
MX2019003026A (es) Compuestos de heteroarilcarboxamida como inhibidores de ripk2.
MX392353B (es) Procedimientos para preparar compuestos de tipo oxatiazina
MX2017005578A (es) Métodos de administración de composiciones de amantadina.
MX382175B (es) Composiciones de profármaco de monometilfumarato
MX374383B (es) Derivados de carboxamida como inhibidores de smurf-1
MX2017000208A (es) Derivados de quinolizinona como inhibidores de pi3k.
MX2018004524A (es) Derivados de eter ciclico de pirazolo[1,5-a]pirimidin-3-carboxiami da.
MX2019011639A (es) Formulacion farmaceutica.